Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosite Triage BNP Heart Failure Blood Test Has 84.4% Sensitivity

This article was originally published in The Gray Sheet

Executive Summary

Biosite Diagnostics' Triage B-Type Natriuretic Peptide (BNP) point-of-care test shows a sensitivity of 84.4% and a specificity of 95.6%, according to data supporting the firm's premarket approval application.
Advertisement

Related Content

Biosite On Track To Earn First Rapid Stroke Assay Approval With PMA Filing
Biosite On Track To Earn First Rapid Stroke Assay Approval With PMA Filing
Biosite Triage BNP Reduces Diagnosis Uncertainty To 11%, NEJM Study Finds
Biosite Triage BNP Reduces Diagnosis Uncertainty To 11%, NEJM Study Finds
Biosite Aiming For Stroke Diagnostic PMA Submission In 2003
Biosite Aiming For Stroke Diagnostic PMA Submission In 2003
Biosite Should Enroll Elderly With Concomitant Illness In CHF Studies - Panel
Biosite Should Enroll Elderly With Concomitant Illness In CHF Studies - Panel
Advertisement
UsernamePublicRestriction

Register

MT014188

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel